Bilastine: a lifetime companion for the treatment of allergies

References

• Pawankar R, Canonica GW, Holgate ST, et al. World Allergy Organization (WAO) white book on allergy: update 2013. Milwaukee, USA: World Allergy Organization; 2013. p. 11–13; 27–31, 60–63.
   Google Scholar
• Björkstén B, Clayton T, Ellwood P, ISAAC Phase III Study Group, et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008;19(2):110–124.
   PubMed Web of Science ®Google Scholar
• Camelo-Nunes IC, Solé D. Allergic rhinitis: indicators of quality of life. J Bras Pneumol. 2010;36(1):124–133.
   PubMed Web of Science ®Google Scholar
• Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–2016.
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128(6):1139–1150.e4.
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–476.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414.
   PubMed Web of Science ®Google Scholar
• Bosma R, van den Bor J, Vischer HF, et al. The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H(1) receptor. Eur J Pharmacol. 2018;5(838):107–111.
   Web of Science ®Google Scholar
• Paśko P, Rodacki T, Domagała-Rodacka R, et al. Second generation H1 – antihistamines interaction with food and alcohol-A systematic review. Biomed Pharmacother. 2017;93:27–39.
   PubMed Web of Science ®Google Scholar
• Corcóstegui R, Labeaga L, Innerárity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D. 2005;6(6):371–384.
   PubMedGoogle Scholar
• Corcóstegui R, Labeaga L, Innerárity A, et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D. 2006;7(4):219–231.
   PubMedGoogle Scholar
• Jauregizar N, de la Fuente L, Lucero ML, et al. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet. 2009;48(8):543–554.
   PubMed Web of Science ®Google Scholar
• Church MK. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm Res. 2011;60(12):1107–1112.
   PubMed Web of Science ®Google Scholar
• Antonijoan R, Coimbra J, García-Gea C, et al. Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers. Curr Med Res Opin. 2017;33(1):129–136.
   PubMed Web of Science ®Google Scholar
• Togawa M, Yamaya H, Rodríguez M, et al. Pharmacokinetics, pharmacodynamics and population pharmacokinetic/pharmacodynamic modelling of bilastine, a second-generation antihistamine, in healthy Japanese subjects. Clin Drug Investig. 2016;36(12):1011–1021.
   PubMed Web of Science ®Google Scholar
• Sádaba B, Gómez-Guiu A, Azanza JR, et al. Oral availability of bilastine. Clin Drug Investig. 2013;33(5):375–381.
   PubMed Web of Science ®Google Scholar
• Coimbra J, Campo C, Labeaga L, et al. Lack of clinical relevance of bilastine-food pharmacokinetic interaction assessed by inhibition of histamine-induced wheal and flare response in healthy volunteers. Skin Allergy Meeting; 2019 April 4–6; Munich, Germany.
   Google Scholar
• Bilastine 20 mg tablets: summary of product characteristics. 2018; [cited 2019 Mar 3]. Available from: http://www.gov.uk/pil-spc.
   Google Scholar
• Sologuren A, Lucero ML, Valiente R, et al. Human mass balance with [14C]-bilastine following oral administration to healthy volunteers. Basic Clin Pharmacol Toxicol. 2009;105(1):106–107.
   Google Scholar
• Lasseter KC, Sologuren A, La Noce A, et al. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency. Clin Drug Investig. 2013;33(9):665–673.
   PubMed Web of Science ®Google Scholar
• Lucero ML, Gonzalo A, Mumford R, et al. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol. 2012;35(Supp1):18–24.
   PubMed Web of Science ®Google Scholar
• Lucero ML, Gonzalo A, Ganza A, et al. Interactions of bilastine, a new oral H1 antihistamine, with human transporter systems. Drug Chem Toxicol. 2012;35(Supp1):8–17.
   PubMed Web of Science ®Google Scholar
• Farré M, Pérez-Mañá C, Papaseit E, et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol. 2014;78(5):970–980.
   PubMed Web of Science ®Google Scholar
• Brożek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958.
   PubMed Web of Science ®Google Scholar
• Menditto E, Costa E, Midão L, et al. Adherence to treatment in allergic rhinitis using mobile technology. The MASK study. Clin Exp Allergy. 2019;49(4):442–460.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: the MASK observational pilot study. Allergy. 2018;73(9):1763–1774.
   PubMed Web of Science ®Google Scholar
• Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2018;14(S2):51.
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010;59(5):391–398.
   PubMed Web of Science ®Google Scholar
• Hashiguchi K, Wakabayashi KI, Togawa M, et al. Therapeutic effect of bilastine in Japanese cedar pollinosis using an artificial exposure chamber (OHIO Chamber). Allergol Int. 2017;66(1):123–131.
   PubMed Web of Science ®Google Scholar
• Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009;64(1):158–165.
   PubMed Web of Science ®Google Scholar
• Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009;39(9):1338–1347.
   PubMed Web of Science ®Google Scholar
• Sastre J, Mullol J, Valero A, Bilastine Study Group, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin. 2012;28(1):121–130.
   PubMed Web of Science ®Google Scholar
• Okubo K, Gotoh M, Asako M, et al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergol Int. 2017;66(1):97–105.
   PubMed Web of Science ®Google Scholar
• Bartra J, Mullol J, Montoro J, et al. Effect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitis. J Investig Allergol Clin Immunol. 2011;21(3):24–33.
   PubMed Web of Science ®Google Scholar
• Dávila I, Sastre J, Mullol J, et al. Effect of bilastine upon nasal obstruction. J Investig Allergol Clin Immunol. 2011;21(3):2–8.
   PubMed Web of Science ®Google Scholar
• Kirmaz C, Aydemir O, Bayrak P, et al. Sexual dysfunction in patients with allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2005;95(6):525–529.
   PubMed Web of Science ®Google Scholar
• Locks RB, Dos Santos K, da Silva J. Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine. Clin Otolaryngol. 2017;42(2):218–224.
   PubMed Web of Science ®Google Scholar
• Jáuregui I, Bartra J, del Cuvillo A, et al. Bilastine and quality of life. J Investig Allergol Clin Immunol. 2011;21(3):16–23.
   PubMed Web of Science ®Google Scholar
• Okubo K, Gotoh M, Togawa M, et al. Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: results of an open-label trial. Auris Nasus Larynx. 2017;44(3):294–301.
   PubMed Web of Science ®Google Scholar
• Spaeth J, Klimek L, Mösges R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy. 1996;51(12):893–906.
   PubMed Web of Science ®Google Scholar
• Vuurman EF, Vuurman LL, Lutgens I, et al. Allergic rhinitis is a risk factor for traffic safety. Allergy. 2014;69(7):906–912.
   PubMed Web of Science ®Google Scholar
• García-Gea C, Martínez-Colomer J, Antonijoan RM, et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol. 2008;28(6):675–685.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs. levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010;65(4):516–528.
   PubMed Web of Science ®Google Scholar
• Hide M, Yagami A, Togawa M, et al. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study. Allergol Int. 2017;66(2):317–325.
   PubMed Web of Science ®Google Scholar
• Krause K, Spohr A, Zuberbier T, et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy. 2013;68(7):921–928.
   PubMed Web of Science ®Google Scholar
• Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66(3):317–330.
   PubMed Web of Science ®Google Scholar
• Yagami A, Furue M, Togawa M, et al. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol. 2017;44(4):375–385.
   PubMed Web of Science ®Google Scholar
• Weller K, Church MK, Hawro T, et al. Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: a real-life study. Allergy. 2018;73(10):2073–2075.
   PubMed Web of Science ®Google Scholar
• Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012;16(14):1999–2005.
   PubMed Web of Science ®Google Scholar
• Jáuregui I, Ramaekers JG, Yanai K, et al. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving. Expert Opin Drug Saf. 2016;15(1):89–98.
   PubMed Web of Science ®Google Scholar
• Kawauchi H, Yanai K, Wang DY, et al. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. IJMS. 2019;20(1)pii:E:213.
   Web of Science ®Google Scholar
• Montoro J, Mullol J, Dávila I, et al. Bilastine and the central nervous system. J Investig Allergol Clin Immunol. 2011;21(3):9–15.
   PubMed Web of Science ®Google Scholar
• García-Gea C, Martínez J, Ballester MR, et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol Clin Exp. 2014;29(2):120–132.
   PubMed Web of Science ®Google Scholar
• Conen S, Theunissen EL, Van Oers AC, et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol. 2011;25(11):1517–1523.
   PubMed Web of Science ®Google Scholar
• Demonte A, Guanti MB, Liberati S, et al. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients. Eur Rev Med Pharmacol Sci. 2018;22(3):820. 8.
   PubMed Web of Science ®Google Scholar
• Reményi Á, Grósz A, Szabó SA, et al. Comparative study of the effect of bilastine and cetirizine on cognitive functions at ground level and at an altitude of 4,000 m simulated in hypobaric chamber: a randomized, double-blind, placebo-controlled, cross-over study. Expert Opin Drug Saf. 2018;17(9):859–868.
   PubMed Web of Science ®Google Scholar
• Valk PJ, Simons R, Jetten AM, et al. Cognitive performance effects of bilastine 20 mg during 6 hours at 8000 ft Cabin Altitude. Aerosp Med Hum Perform. 2016;87(7):622–627.
   PubMed Web of Science ®Google Scholar
• Graff C, Struijk JJ, Kanters JK, et al. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig. 2012;32(5):339–351.
   PubMed Web of Science ®Google Scholar
• Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol. 2012;52(6):893–903.
   PubMed Web of Science ®Google Scholar
• Cataldi M, Maurer M, Taglialatela M, et al. Cardiac safety of second-generation H1-antihistamines when updosed in chronic spontaneous urticaria. Clin Exp Allergy. 2019.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency CMDh. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s). 2017; [cited 10 Sep 2019]. Available from: https://www.ema.europa.eu/en/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00003163/201703_en.pdf.
   Google Scholar
• Yáñez A, Cho SH, Soriano JB, et al. Asthma in the elderly: what we know and what we have yet to know. World Allergy Organ J. 2014;7(1):8.
   PubMedGoogle Scholar
• Bozek A. Pharmacological management of allergic rhinitis in the elderly. Drugs Aging. 2017;34(1):21–28.
   PubMed Web of Science ®Google Scholar
• De Martinis M, Sirufo MM, Ginaldi L. Allergy and aging: an old/new emerging health issue. A&D. 2017;8(2):162–175.
   Web of Science ®Google Scholar
• Milgrom H, Huang H. Allergic disorders at a venerable age: a mini-review. Gerontology. 2014;60(2):99–107.
   PubMed Web of Science ®Google Scholar
• Pinto JM, Jeswani S. Rhinitis in the geriatric population. Allergy Asthma Clin Immunol. 2010;6(1):10.
   PubMedGoogle Scholar
• Farage MA, Miller KW, Elsner P, et al. Functional and physiological characteristics of the aging skin. Aging Clin Exp Res. 2008;20(3):195–200.
   PubMed Web of Science ®Google Scholar
• Ventura MT, Scichilone N, Gelardi M, et al. Management of allergic disease in the elderly: key considerations, recommendations and emerging therapies. Expert Rev Clin Immunol. 2015;11(11):1219–1228.
   PubMed Web of Science ®Google Scholar
• Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.
   PubMed Web of Science ®Google Scholar
• Morin L, Johnell K, Laroche ML, et al. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. CLEP. 2018;10:289–298.
   Web of Science ®Google Scholar
• Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.
   PubMed Web of Science ®Google Scholar
• Ellam T, Twohig H, Khwaja A. Chronic kidney disease in elderly people: disease or disease label? BMJ. 2016;352:h6559.
   PubMed Web of Science ®Google Scholar
• Eshkoor SA, Hamid TA, Mun CY, et al. Mild cognitive impairment and its management in older people. Clin Interv Aging. 2015;10:687–693.
   PubMed Web of Science ®Google Scholar
• Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15–28.
   PubMed Web of Science ®Google Scholar
• Sologuren A, Viñas R, Cordón E, et al. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria. Allergy Asthma Proc. 2018;39(4):299–304.
   PubMed Web of Science ®Google Scholar
• Aït-Khaled N, Pearce N, Anderson HR, ISAAC Phase Three Study Group, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) phase three. Allergy. 2009;64(1):123–148.
   PubMed Web of Science ®Google Scholar
• Kudryavtseva AV, Neskorodova KA, Staubach P. Urticaria in children and adolescents: an updated review of the pathogenesis and management. Pediatr Allergy Immunol. 2019;30(1):17–24.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Ha EK, Jee HM, et al. Prevalence and risk factors of urticaria with a focus on chronic urticaria in children. Allergy Asthma Immunol Res. 2017;9(3):212–219.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994;93(2):413–423.
   PubMed Web of Science ®Google Scholar
• Keil T, Bockelbrink A, Reich A, et al. The natural history of allergic rhinitis in childhood. Pediatr Allergy Immunol. 2010;21(6):962–969.
   PubMed Web of Science ®Google Scholar
• Blaiss MS, Hammerby E, Robinson S, et al. The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: a literature review. Ann Allergy Asthma Immunol. 2018;121(1):43–52.e3.
   PubMed Web of Science ®Google Scholar
• Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155(1):145–151.
   PubMed Web of Science ®Google Scholar
• Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007;120(2):381–387.
   PubMed Web of Science ®Google Scholar
• Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergológica 2005. J Investig Allergol Clin Immunol. 2009;19(2):21–26.
   PubMed Web of Science ®Google Scholar
• Bilastine 10 mg orodispersible tablets: summary of product characteristics; 2018 [cited 2019 Mar 3]. Available from: http://www.gov.uk/pil-spc.
   Google Scholar
• Bilastine 2.5 mg/ml oral solution: summary of product characteristics; 2018 [cited 2019 Mar 3]. Available from: http://www.gov.uk/pil-spc.
   Google Scholar
• Vozmediano V, Sologuren A, Lukas JC, et al. Model informed pediatric development applied to bilastine: ontogenic pk model development, dose selection for first time in children and PK study design. Pharm Res. 2017;34(12):2720–2734.
   PubMed Web of Science ®Google Scholar
• Vozmediano V, Lukas JC, Encinas E, et al. Model-informed pediatric development applied to bilastine: analysis of the clinical PK data and confirmation of the dose selected for the target population. Eur J Pharm Sci. 2019;128:180–192.
   PubMed Web of Science ®Google Scholar
• Novák Z, Yáñez A, Kiss I, et al. Bilastine Paediatric Safety Study Group”. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatr Allergy Immunol. 2016;27(5):493–498.
   PubMed Web of Science ®Google Scholar
• Roberts G, Xatzipsalti M, Borrego LM, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68(9):1102–1116.
   PubMed Web of Science ®Google Scholar
• Fitzsimons R, van der Poel LA, Thornhill W, et al. Antihistamine use in children. Arch Dis Child Educ Pract Ed. 2015;100(3):122–131.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van Cauwenberge P, Bachert C, et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy. 2003;58(3):192–197.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Ansótegui I, Canonica GW, et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012;28(1):131–139.
   PubMed Web of Science ®Google Scholar